Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A (July 2019). "The role of PET/CT in the modern treatment of Hodgkin lymphoma". Cancer Treatment Reviews. Cilt 77. ss. 44-56. doi:10.1016/j.ctrv.2019.06.002. PMID31260900.
McCarten KM, Nadel HR, Shulkin BL, Cho SY (October 2019). "Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma". Pediatric Radiology. 49 (11). ss. 1545-1564. doi:10.1007/s00247-019-04529-8. PMID31620854.
Pauls S, Buck AK, Hohl K, Halter G, Hetzel M, Blumstein NM, ve diğerleri. (2007). "Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT". Nuklearmedizin. 46 (1). ss. 09-14. doi:10.1055/s-0037-1616618. ISSN0029-5566.
Chao F, Zhang H (2012). "PET/CT in the staging of the non-small-cell lung cancer". Journal of Biomedicine & Biotechnology. Cilt 2012. s. 783739. doi:10.1155/2012/783739. PMC3346692 $2. PMID22577296.
Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, ve diğerleri. (Cochrane Haematology Group) (January 2020). "Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies". The Cochrane Database of Systematic Reviews. 1 (1). ss. CD012643. doi:10.1002/14651858.CD012643.pub3. PMC6984446 $2. PMID31930780.
la Fougère, C.; Rominger, A.; Förster, S.; Geisler, J.; Bartenstein, P. (May 2009). "PET and SPECT in epilepsy: A critical review". Epilepsy & Behavior. 15 (1). ss. 50-55. doi:10.1016/j.yebeh.2009.02.025. PMID19236949.
Hodolic, Marina; Topakian, Raffi; Pichler, Robert (1 Eylül 2016). "18 F-fluorodeoxyglucose and 18 F-flumazenil positron emission tomography in patients with refractory epilepsy". Radiology and Oncology. 50 (3). ss. 247-253. doi:10.1515/raon-2016-0032. PMC5024661 $2. PMID27679539.
Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R, ve diğerleri. (May 2010). "Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors". Journal of Cerebral Blood Flow and Metabolism. 30 (5). ss. 985-93. doi:10.1038/jcbfm.2009.269. PMC2949183 $2. PMID20029452.
Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J (December 2002). "Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors". Synapse. 46 (3). ss. 170-88. doi:10.1002/syn.10128. PMID12325044.
Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, ve diğerleri. (July 2006). "D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia". Schizophrenia Research. 85 (1–3). ss. 232-44. doi:10.1016/j.schres.2006.03.042. PMID16713185.
Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, ve diğerleri. (June 2002). "Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography". Circulation. 105 (23). ss. 2708-11. doi:10.1161/01.CIR.0000020548.60110.76. PMID12057982.
Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A (July 2019). "The role of PET/CT in the modern treatment of Hodgkin lymphoma". Cancer Treatment Reviews. Cilt 77. ss. 44-56. doi:10.1016/j.ctrv.2019.06.002. PMID31260900.
McCarten KM, Nadel HR, Shulkin BL, Cho SY (October 2019). "Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma". Pediatric Radiology. 49 (11). ss. 1545-1564. doi:10.1007/s00247-019-04529-8. PMID31620854.
Chao F, Zhang H (2012). "PET/CT in the staging of the non-small-cell lung cancer". Journal of Biomedicine & Biotechnology. Cilt 2012. s. 783739. doi:10.1155/2012/783739. PMC3346692 $2. PMID22577296.
Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, ve diğerleri. (Cochrane Haematology Group) (January 2020). "Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies". The Cochrane Database of Systematic Reviews. 1 (1). ss. CD012643. doi:10.1002/14651858.CD012643.pub3. PMC6984446 $2. PMID31930780.
la Fougère, C.; Rominger, A.; Förster, S.; Geisler, J.; Bartenstein, P. (May 2009). "PET and SPECT in epilepsy: A critical review". Epilepsy & Behavior. 15 (1). ss. 50-55. doi:10.1016/j.yebeh.2009.02.025. PMID19236949.
Hodolic, Marina; Topakian, Raffi; Pichler, Robert (1 Eylül 2016). "18 F-fluorodeoxyglucose and 18 F-flumazenil positron emission tomography in patients with refractory epilepsy". Radiology and Oncology. 50 (3). ss. 247-253. doi:10.1515/raon-2016-0032. PMC5024661 $2. PMID27679539.
Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R, ve diğerleri. (May 2010). "Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors". Journal of Cerebral Blood Flow and Metabolism. 30 (5). ss. 985-93. doi:10.1038/jcbfm.2009.269. PMC2949183 $2. PMID20029452.
Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J (December 2002). "Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors". Synapse. 46 (3). ss. 170-88. doi:10.1002/syn.10128. PMID12325044.
Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, ve diğerleri. (July 2006). "D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia". Schizophrenia Research. 85 (1–3). ss. 232-44. doi:10.1016/j.schres.2006.03.042. PMID16713185.
Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, ve diğerleri. (June 2002). "Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography". Circulation. 105 (23). ss. 2708-11. doi:10.1161/01.CIR.0000020548.60110.76. PMID12057982.